Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2023BMJ MedicineOpen Access

This review highlights key pathophysiological concepts and emerging therapeutic directions for pulmonary arterial hypertension, targeting inflammation, cellular metabolism, genetics, and epigenetics.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Current treatments for pulmonary hypertension target pathways controlling pulmonary vascular tone and proliferation, but have limited efficacy on patient outcomes.

Design

Review

Key result

This review highlights key pathophysiological concepts and emerging therapeutic directions for pulmonary arterial hypertension, targeting inflammation, cellular metabolism, genetics, and epigenetics.

Authors

SBSimon BousseauRFRafael Sobrano FaisSGSue Gu

Discussion

Loading...

Member takes

Overview

Review highlights emerging PH therapies; leaves open their efficacy in diverse populations without dedicated RCTs.

Structured PICO

P
Population
Patients with pulmonary hypertension, with a focus on pulmonary arterial hypertension
I
Intervention
Current and emerging therapeutic interventions targeting inflammation, cellular metabolism, genetics and epigenetics, sex hormone signalling, bone morphogenetic protein signalling, and inhibition of tyrosine kinase receptors

This review summarizes the complex pathophysiology of pulmonary arterial hypertension and highlights emerging therapeutic targets beyond traditional pulmonary vasodilator pathways.

Cite This Study

Bousseau et al. (2023) conducted a review in Pulmonary hypertension. This review highlights key pathophysiological concepts and emerging therapeutic directions for pulmonary arterial hypertension, targeting inflammation, cellular metabolism, genetics, and epigenetics.

synapsesocial.com/papers/6a7c85797622cda7f36e9ce3https://doi.org/10.1136/bmjmed-2022-000137
View Full Paper
Ask AI
Bookmark
Share